학술논문
Health-Related Quality of Life in HIV Patients Switching to Twice-Daily Indinavir/Ritonavir Regimen or Continuing with Three-Times-Daily Indinavir-Based Therapy
Document Type
Article
Author
Badía, Xavier; Podzamczer, Daniel; Moral, Irene; Roset, Montse; Arnaiz, Joan A; Loncà, Montse; Casiró, Arnaldo; Rosón, Beatriz; Gatell, Jose M; Grinberg, N; Puentes, T; Furst, MJ López; Julio Méndez, Sanatorio; Lupo, S; Suárez, C; Agostini, M; Cassetti, I; Bologna, R; Salud, Helios; Cahn, P; Patterson, P; Krolewiecki, A; David, DO; Luna, N; Cruceta, A; Pich, J; Varea, S; Carné, X; Mallolas, J; Clotet, B; Romeu, J; Cruz, L; Arrizabalaga, J; Iribarren, JA; Rodríguez, F; Von Wichmann, MA; Jimeno, B; Pulido, F; Rubio, R; Flores, J; González-Lahoz, J; Rodríguez-Rosado, R; Núñez, M
Source
Antiviral Therapy; August 2004, Vol. 9 Issue: 6 p979-985, 7p
Subject
Language
ISSN
13596535
Abstract
Objective To evaluate health-related quality of life (HRQoL) changes in patients treated with indinavir three-times daily after switching to a twice-daily indinavir/ritonavir regimen or continuing with the same regimen.Methods Patients on HAART including indinavir three-times-daily with undetectable viral load were randomly assigned to continue with this therapy or to change to a twice-daily indinavir/ritonavir (800/100 mg) regimen. The Medical Outcomes Study HIV Health Survey (MOS-HIV) questionnaire was used as the HRQoL measure.Results A total of 118 patients participated in the study, of which 59 (50%) were randomly assigned to continue with the three-times-daily regimen. Patients had a mean age of 39 years and 80% of them were male. At baseline, subjects included in the three-times-daily group presented a significantly greater number of symptoms than subjects in the twice-daily group, but no statistically significant differences were observed in MOS-HIV scores between the groups. In the intention-to-treat (ITT) analysis, a reduction in HRQoL scores was observed in both groups, which was greater in the twice-daily group. In the per protocol analysis, reduction of HRQoL was minimal.Conclusions A HRQoL deterioration, greater in the twice-daily group, was observed in this study in the ITT analysis, while HRQoL remained stable in both groups in patients who continued with and tolerated the allocated regimen.